ANVS Annovis Bio Inc

Price (delayed)

$12.64

Market cap

$141.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.13

Enterprise value

$138.07M

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). ...

Highlights
ANVS's equity has dropped by 117% year-on-year but it has surged by 57% since the previous quarter
The net income has dropped by 59% year-on-year but it is up by 15% since the previous quarter
The quick ratio has dropped by 79% year-on-year and by 52% since the previous quarter

Key stats

What are the main financial stats of ANVS
Market
Shares outstanding
11.17M
Market cap
$141.21M
Enterprise value
$138.07M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$47.53M
EBITDA
-$47.53M
Free cash flow
-$35.37M
Per share
EPS
-$5.13
Free cash flow per share
-$3.33
Book value per share
-$0.3
Revenue per share
$0
TBVPS
$0.74
Balance sheet
Total assets
$7.81M
Total liabilities
$11.17M
Debt
$0
Equity
-$3.35M
Working capital
$2.94M
Liquidity
Debt to equity
0
Current ratio
1.6
Quick ratio
0.64
Net debt/EBITDA
0.07
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-372.4%
Return on equity
-1,166.8%
Return on invested capital
-3,586.1%
Return on capital employed
-1,615%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANVS stock price

How has the Annovis Bio stock price performed over time
Intraday
3.95%
1 week
-18.24%
1 month
116.07%
1 year
-8.54%
YTD
-32.41%
QTD
119.44%

Financial performance

How have Annovis Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$42.88M
Net income
-$47.53M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 59% year-on-year but it is up by 15% since the previous quarter
The company's operating income fell by 42% YoY but it rose by 4.8% QoQ

Growth

What is Annovis Bio's growth rate over time

Valuation

What is Annovis Bio stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 41% year-on-year but it has grown by 18% since the previous quarter
ANVS's equity has dropped by 117% year-on-year but it has surged by 57% since the previous quarter

Efficiency

How efficient is Annovis Bio business performance
The company's return on equity has shrunk by 106% QoQ
ANVS's ROIC has soared by 84% YoY but it is down by 42% QoQ
The return on assets has declined by 14% since the previous quarter

Dividends

What is ANVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANVS.

Financial health

How did Annovis Bio financials performed over time
Annovis Bio's total assets is 30% lower than its total liabilities
ANVS's total liabilities has soared by 106% YoY but it is down by 38% QoQ
The quick ratio has dropped by 79% year-on-year and by 52% since the previous quarter
The company's debt is 100% higher than its equity
ANVS's equity has dropped by 117% year-on-year but it has surged by 57% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.